Gastroenterologie
a hepatologie

Infliximab does not increase the risk of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA

Marta Kostrejová ^{Orcid.org  1,2}, Martin Bortlík ^{Orcid.org  3,4,5}, Milan Lukáš ^{Orcid.org  3}, Dana Ďuricová ^{Orcid.org  3}, Robert Mudr ^{Orcid.org  6}, Arnošt Komárek ^{Orcid.org  7}, Richard Sequens ^{Orcid.org  8}

+ Affiliation
¹ Klinické a výzkumné centrum pro střevní záněty ISCARE a.s. a 1. LF UK Praha
² Nemocnice Milosrdných sester sv. Karla Boromejského v Praze
³ IBD clinical and research centre ISCARE a.s., Prague, Czech Republic
⁴ Department of Internal Medicine, 1st Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic
⁵ Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
⁶ Gastroenterologické oddělení, Nemocnice Milosrdných sester sv. Karla Boromejského, Praha
⁷ Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics of Charles University, Prague
⁸ Chirurgické oddělení, NH Hospital a.s., Nemocnice Hořovice, Chirurgické oddělení, Nemocnice Milosrdných sester sv. Karla Boromejského v Praze

Summary

Introduction and aim: Patients with ulcerative colitis (UC) treated with infliximab (IFX) preoperatively are theoretically at increased risk of complications after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). The aim was to compare the occurrence of early postoperative complications among patients treated and not treated with IFX.

Methods: A retrospective analysis of different types of early postoperative complications in UC patients treated and not treated with IFX.

Results: Between January 2006 and December 2012,138 UC patients underwent surgical therapy. Of these patients, 108 had restorative proctocolectomy and IPAA. Forty-seven patients received IFX preoperatively (IFX group), while 61 did not receive any IFX (No-IFX group). In total, early complications occurred in 40.4% of patients in the IFX group, and in 44.3% in the No-IFX group. Using logistic regression analysis, no statistically significant difference was found in the occurrence of any particular type of both surgical and non-surgical complications.

Conclusion: We did not observe an increased occurrence of early postoperative complications in UC patients after a three-stage restorative proctocolectomy with IPAA.

Keywords

infliximab, postoperative complications, ulcerative colitis

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users